The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
Open accessAbstract
Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has led to unprecedented responses in patients with high-risk hematologic malignancies. However, up to 60% of patients still experience disease relapse and up to 80% of patients experience CAR-mediated toxicities, such as cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome. We investigated the role of the intestinal microbiome on these outcomes in a multicenter study of patients with B cell lymphoma and leukemia. We found in a retrospective cohort (n = 228) that exposure to antibiotics, in particular piperacillin/tazobactam, meropenem and imipenem/cilastatin (P-I-M), in the 4 weeks before therapy was associated with worse survival and increased neurotoxicity. In stool samples from a prospective cohort of CAR T cell recipients (n = 48), the fecal microbiome was altered at baseline compared to healthy controls. Stool sample profiling by 16S ribosomal RNA and metagenomic shotgun sequencing revealed that clinical outcomes were associated with differences in specific bacterial taxa and metabolic pathways. Through both untargeted and hypothesis-driven analysis of 16S sequencing data, we identified species within the class Clostridia that were associated with day 100 complete response. We concluded that changes in the intestinal microbiome are associated with clinical outcomes after anti-CD19 CAR T cell therapy in patients with B cell malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, CAR T-cells,237,238 hematopoietic stem cell transplantation,239 and vaccines244 are all affected by gut microbial composition.”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [238]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the demonstration of the deleterious impact of antibiotics on the efficacy of immune checkpoint blockade (ICB) 3,4 and chimeric antigen receptor (CAR) T cell therapies 5”
From Impact of the ONCOBIOME network in cancer microbiome research (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“Interestingly, treatment of B cell lymphoma and leukemia patients with broad-spectrum antibiotics prior to CD19-targeted chimeric antigen receptor (CAR)-T cell therapy was recently associated with reduced survival and increased neurotoxicity24.”
From A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy (2023) · cites this paper as [24]
In the citing paper
“These findings were replicated independently in a German and a US cohorts and are in line with data of a recent US study of lymphoma and acute lymphoblastic leukemia patients24.”
From A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy (2023) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
KEGG: Kyoto Encyclopedia of Genes and Genomes
Kanehisa, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.27 · Cited by 37,077
DADA2: High–resolution sample inference from Illumina amplicon data
Callahan, B. J., McMurdie, P. J., Rosen, M. J., Han, A. W., Johnson, A. J. A., & Holmes, S. P. (2016) · Nature Methods · doi:10.1038/nmeth.3869 · Cited by 35,698
KEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232
Wickham, H., Averick, M., Bryan, J., Chang, W., McGowan, L., François, R., Grolemund, G., Hayes, A., Henry, L., Hester, J., et al. (2019) · Journal of Open Source Software · doi:10.21105/joss.01686 · Cited by 22,138
BLAST+: architecture and applications
Camacho, C., Coulouris, G., Avagyan, V., Ma, N., Papadopoulos, J., Bealer, K., & Madden, T. L. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-421 · Cited by 22,074
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
An Ordination of the Upland Forest Communities of Southern Wisconsin
Bray, J. R., & Curtis, J. T. (1957) · Ecological Monographs · doi:10.2307/1942268 · Cited by 11,716
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citationTisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Self-citationGut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Cited by
γδ T cells: origin and fate, subsets, diseases and immunotherapy
Hu, Y., Hu, Q., Li, Y., Lu, L., Xiang, Z., Yin, Z., Kabelitz, D., & Wu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01653-8 · Cited by 382
Rejeski, K., Subklewe, M., Aljurf, M., Bachy, E., Balduzzi, A., Barba, P., Bruno, B., Benjamin, R., Carrabba, M. G., Chabannon, C., et al. (2023) · Blood · doi:10.1182/blood.2023020578 · Cited by 358
Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications
Zhao, L.-Y., Mei, J.-X., Yu, G., Lei, L., Zhang, W.-H., Liu, K., Chen, X.-L., Kołat, D., Yang, K., & Hu, J.-K. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01406-7 · Cited by 359
“meropenem, piperacillin/tazobactam and imipenem/cilastatin, during the 4 weeks before CAR-T-cell therapy was associated with worse clinical outcomes and prognosis; furthermore, they found a higher abundance and richness of Ruminococcus, Bacteroides and Faecalibacterium in stool samples were correlated with a better re…”
ResultA systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy
Cordas dos Santos, D. M., Tix, T., Shouval, R., Gafter-Gvili, A., Alberge, J.-B., Cliff, E. R. S., Theurich, S., von Bergwelt-Baildon, M., Ghobrial, I. M., Subklewe, M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03084-6 · Cited by 287
“Indeed, both host factors (for example, performance status, comorbidities) and disease-specific factors (for example, tumor load, systemic inflammation) could have contributed to the observed variation of NRM rates across CAR T cell products 28,78–81 .”
Self-citationTargeting the gut microbiota for cancer therapy
Fernandes, M. R., Aggarwal, P., Costa, R. G. F., Cole, A. M., & Trinchieri, G. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00513-x · Cited by 290
Metadata
- Authors
- Smith, M., Dai, A., Ghilardi, G., Amelsberg, K. V., Devlin, S. M., Pajarillo, R., Slingerland, J. B., Beghi, S., Herrera, P. S., Giardina, P., Clurman, A., Dwomoh, E., Armijo, G., Gomes, A. L. C., Littmann, E. R., Schluter, J., Fontana, E., Taur, Y., Park, J. H., Palomba, M. L., Halton, E., Ruiz, J., Jain, T., Pennisi, M., Afuye, A. O., Perales, M.-A., Freyer, C. W., Garfall, A., Gier, S., Nasta, S., Landsburg, D., Gerson, J., Svoboda, J., Cross, J., Chong, E. A., Giralt, S., Gill, S. I., Riviere, I., Porter, D. L., Schuster, S. J., Sadelain, M., Frey, N., Brentjens, R. J., June, C. H., Pamer, E. G., Peled, J. U., Facciabene, A., van den Brink, M. R. M., & Ruella, M.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Hospital of the University of Pennsylvania (US)
- University of Chicago (US)
- Johns Hopkins University (US)
- University of Milan (IT)
- University of Pennsylvania (US)
- Abramson Cancer Center (US)
- Corresponding author
- Facciabene, Andrea
- van den Brink, Marcel R. M.
- Ruella, Marco
- ORCID
- Smith, Melody
- Dai, Anqi
- Ghilardi, Guido
- Amelsberg, Kimberly V.
- Devlin, Sean M.
- Pajarillo, Raymone
- Slingerland, John B.
- Beghi, Silvia
- Giardina, Paul
- Clurman, Annelie
- Armijo, Gabriel
- Gomes, Antonio L. C.
- Littmann, Eric R.
- Schluter, Jonas
- Fontana, Emily
- Taur, Ying
- Park, Jae H.
- Palomba, Maria Lia
- Jain, Tania
- Pennisi, Martina
- Afuye, Aishat Olaide
- Perales, Miguel-Angel
- Freyer, Craig W.
- Garfall, Alfred
- Nasta, Sunita
- Landsburg, Daniel
- Gerson, James
- Svoboda, Jakub
- Cross, Justin
- Chong, Elise A.
- Giralt, Sergio
- Gill, Saar I.
- Porter, David L.
- Schuster, Stephen J.
- Sadelain, Michel
- Frey, Noelle
- Brentjens, Renier J.
- June, Carl H.
- Pamer, Eric G.
- Peled, Jonathan U.
- Facciabene, Andrea
- van den Brink, Marcel R. M.
- Ruella, Marco
- Venue
- Nature Medicine
- Published
- 2022-03-14
- Volume
- 28
- Issue
- 4
- Pages
- 713-723
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC9434490
- OpenAlex
- W4221064629
- Cited by
- 349
- References
- 74
- Citations by year
- 2026: 78 · 2025: 87 · 2024: 73 · 2023: 84 · 2022: 27
- FWCI
- 28.09
- Type
- journal article
- Language
- en
- Update notices
- correction (2022-10-17)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01-HL125571, R01-HL123340)
- American Society of Hematology (AMFDP)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- gut microbiota, CD19 CAR T-cell therapy, B-cell lymphoma, leukemia, antibiotic exposure, piperacillin-tazobactam, meropenem, imipenem/cilastatin, Clostridia, immune effector cell-associated neurotoxicity syndrome, cytokine release syndrome, treatment toxicity, treatment response, survival, hematologic malignancies
- MeSH terms
- Gastrointestinal Microbiome, Receptors, Chimeric Antigen, Humans, Prospective Studies, Retrospective Studies, Immunotherapy, Adoptive, Antigens, CD19, Neurotoxicity Syndromes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. https://app.cochat.ai/papers/10.1038/s41591-022-01702-9
- The paper
- Smith, M., Dai, A., Ghilardi, G., Amelsberg, K. V., Devlin, S. M., Pajarillo, R., Slingerland, J. B., Beghi, S., Herrera, P. S., Giardina, P., Clurman, A., Dwomoh, E., Armijo, G., Gomes, A. L. C., Littmann, E. R., Schluter, J., Fontana, E., Taur, Y., Park, J. H., . . . Ruella, M. (2022). Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nature Medicine. https://doi.org/10.1038/s41591-022-01702-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.